Global Cancer Gene Therapy Market Size, Share & Trends Analysis Report (2025–2032)
By Therapy Type, Vector Type, Cancer Type, End-use, Region, and Segment Forecasts
Executive Summary
The global cancer gene therapy market is experiencing rapid growth driven by advancements in gene editing technologies such as CRISPR, increasing oncology research investments, and rising demand for personalized medicine. Gene-based therapies are emerging as highly targeted treatment approaches, offering improved outcomes compared to conventional cancer therapies.
Key Market Drivers
- Advancements in CRISPR and gene editing technologies
- Growing demand for personalized cancer treatments
- Increasing investment in biotechnology research
- Rising global cancer incidence
Market Size & Share
The market is projected to reach USD 28 Billion by 2032, growing at a CAGR of 17%.
Market Forecast2025 - 2032
Revenue by Region (%)
Market Dynamics
Drivers
- Advancements in CRISPR and gene editing technologies
- Growing demand for personalized cancer treatments
- Increasing investment in biotechnology research
- Rising global cancer incidence
Restraints
- High cost of gene therapy treatments
- Regulatory and clinical approval challenges
- Limited large-scale manufacturing capacity
Opportunities
- Expansion of CAR-T and gene-modified immunotherapies
- Advancements in viral and non-viral delivery systems
- Growth in emerging healthcare markets
Challenges
- Safety concerns and long-term efficacy validation
- Complex production and distribution processes
Market Segmentation
By Deployment
- Gene Replacement Therapy
- Gene Editing Therapy
- Oncolytic Viral Therapy
- Immunogene Therapy
By Offering
- Viral Vectors
- Non-viral Vectors
By End-user Industry
- Hospitals and Cancer Treatment Centers
- Specialty Clinics
- Research & Academic Institutes
- Biotechnology and Pharmaceutical Companies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Segment Share Analysis
Trends and Insights
Automation and modular investments are unlocking operational margins.
Competitive Landscape
- Concentration: Moderately Consolidated
- Development of gene-edited immune cell therapies
- Expansion of viral vector manufacturing capacity
Sentiment
Geography Analysis
Regional Coverage
North America
North America dominates the market due to strong biotechnology ecosystem, advanced research infrastructure, and high investment in gene therapy clinical trials.
Share: 45%
Asia Pacific
Asia Pacific is the fastest-growing region driven by increasing healthcare investments, expanding biotech research, and government support for genomic innovation.
Share: 20%
Competitive Landscape
The industry structure is best characterized as moderately consolidated.
Top Players
- 1Novartis AG
- 2Gilead Sciences (Kite Pharma)
- 3Bristol Myers Squibb
- 4Bluebird Bio
- 5CRISPR Therapeutics
- 6Intellia Therapeutics
- 7Sangamo Therapeutics
- 8Editas Medicine
- 9BioNTech SE
- 10Amgen Inc.
Strategic Initiatives
- ●Development of gene-edited immune cell therapies
- ●Expansion of viral vector manufacturing capacity
- ●Strategic partnerships between biotech and pharma companies
Recent Developments
Advanced CRISPR-based gene therapy trials for oncology treatments
Research Methodology
Primary Research
Interviews with oncology researchers, biotech companies, and healthcare providers.
Secondary Research
Clinical trial data, scientific publications, and industry reports.
Market Estimation
Top-down and bottom-up approaches.
Forecasting Approach
CAGR-based projections using clinical adoption trends.
Key Assumptions
Continued advancements in gene editing and increasing adoption of personalized therapies.
Key Questions Answered
Report updated on: Recently Published
Table of Contents
Choose License
INSTANT ACCESSTailor-Made
Market Intelligence Solutions
Leading market research company offering custom market research, market research reports, and industry research. Gain actionable market analysis and global market research, empowering enterprises and startups to outpace competitors with data-backed strategies.